Pyxis Oncology files Form 3 beneficial ownership statement for GordonMD Global Investments LP
PYXS•Event and filing dates
The event date was June 30, 2026; the statement was signed July 10, 2026.
Warrants and exercisability terms reported
The filing also reported 4,900,039 common stock purchase warrants, expiring July 2, 2029, with an exercise price of $3.29.
The warrants become exercisable on the earlier of the issuer’s first public MICVO Phase 1 monotherapy data disclosure or Oct. 1, 2026.
Form 3 discloses GordonMD Global Investments as 10% owner
Pyxis Oncology Form 3 disclosed GordonMD Global Investments as a 10% owner, reporting indirect ownership of 10,024,909 common shares.
